• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy.

作者信息

Ito T, Ohashi H, Kagami Y, Ichikawa A, Saito H, Hotta T

机构信息

First Department of Internal Medicine, Nagoya University School of Medicine, Japan.

出版信息

Leukemia. 1994 May;8(5):839-43.

PMID:7910221
Abstract

We performed X-linked restriction fragment length polymorphism (RFLP)-methylation analysis to study the clonality of hematopoiesis in five patients with myelodysplastic syndromes (MDS), who had responded to chemotherapy. Two patients had MDS in blast crisis, two had refractory anemia with an excess of blasts in transformation (RAEB-T), and one had acute myelogenous leukemia with trilineage myelodysplasia (AML-TMDS). Following the administration of low-dose cytarabine therapy or of conventional intensive chemotherapy, we observed a reversion to polyclonal hematopoiesis in three patients who achieved a complete remission (CR). Polyclonal hematopoiesis persisted in one patient in CR, and monoclonal hematopoiesis persisted in another patient of minor response. These results indicate that polyclonal hematopoiesis can be restored in some MDS patients who achieved CR. We are encouraged, therefore, to administer intensive consolidation chemotherapy to prolong the duration of remission.

摘要

相似文献

1
Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy.
Leukemia. 1994 May;8(5):839-43.
2
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.采用伊达比星、阿糖胞苷、依托泊苷及粒细胞集落刺激因子预激进行强化化疗治疗晚期骨髓增生异常综合征和高危急性髓系白血病患者。
Ann Hematol. 2004 Aug;83(8):498-503. doi: 10.1007/s00277-004-0889-0. Epub 2004 May 20.
3
[Low-dose chemotherapy].[低剂量化疗]
Rinsho Ketsueki. 1996 Sep;37(9):777-81.
4
Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.伊达比星与阿糖胞苷用于高危骨髓增生异常综合征的诱导缓解及维持治疗
Haematologica. 1997 Nov-Dec;82(6):660-3.
5
Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.伊达比星和阿糖胞苷用于高危骨髓增生异常综合征的诱导和维持治疗
Haematologica. 1997 Sep-Oct;82(5 Suppl):9-12.
6
Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).急性髓系白血病(M2)成功治疗后出现的伴有5号染色体单体的治疗相关骨髓增生异常综合征
Am J Hematol. 2005 Jun;79(2):136-41. doi: 10.1002/ajh.20329.
7
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).针对预后不良的骨髓增生异常综合征(MDS)以及病程超过6个月的MDS继发的急性髓系白血病(sAML)进行强化化疗。欧洲癌症研究与治疗组织白血病协作组(EORTC-LCG)的一项初步研究。
Leukemia. 1995 Nov;9(11):1805-11.
8
[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].5例初发急性髓系白血病伴三系骨髓发育异常(AML/TMDS)患者采用小剂量依托泊苷持续静脉滴注、小剂量阿糖胞苷联合米托蒽醌(MEtA)治疗后达到完全缓解。
Gan To Kagaku Ryoho. 2004 Jul;31(7):1119-23.
9
A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.低剂量阿糖胞苷与依托泊苷联合化疗用于高危骨髓增生异常综合征及其白血病期:一项初步研究。
Cancer. 1996 Aug 1;78(3):422-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<422::AID-CNCR7>3.0.CO;2-L.
10
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Leukemia. 2003 Sep;17(9):1827-33. doi: 10.1038/sj.leu.2403035.